<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6896409</article-id><article-id pub-id-type="pmid">31790601</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1697251</article-id><article-id pub-id-type="publisher-id">1697251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Carbonic anhydrase IX as a novel candidate in liquid biopsy</article-title><alt-title alt-title-type="running-authors">O. Ozensoy Guler et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ozensoy Guler</surname><given-names>Ozen</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu. T.</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3314-2411</contrib-id><name><surname>Capasso</surname><given-names>Clemente</given-names></name><xref ref-type="aff" rid="AF0003"><sup>c</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Medical Biology, Faculty of Medicine, Yildirim Beyazit University</institution>, Ankara, <country>Turkey</country>; </aff><aff id="AF0002"><label>b</label><institution>Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico</institution>, Firenze, <country>Italy</country>; </aff><aff id="AF0003"><label>c</label><institution>Department of Biology, Agriculture and Food Sciences, Institute of Biosciences and Bioresources, CNR</institution>, Napoli, <country>Italy</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Clemente Capasso <email>clemente.capasso@ibbr.cnr.it</email><institution>Department of Biology, Agriculture and Food Sciences, Institute of Biosciences and Bioresources, CNR</institution>, <addr-line>Via Pietro Castellino, 111 &#x02013; 80131</addr-line>, Napoli, <country>Italy</country></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>2</day><month>12</month><year>2019</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="25">255</fpage><lpage>260</lpage><history><date date-type="received"><day>05</day><month>11</month><year>2019</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1697251.pdf"/><abstract><title>Abstract</title><p>Among the diagnostic techniques for the identification of tumour biomarkers, the liquid biopsy is considered one that offers future research on precision diagnosis and treatment of tumours in a non-invasive manner. The approach consists of isolating tumor-derived components, such as circulating tumour cells (CTC), tumour cell-free DNA (ctDNA), and extracellular vesicles (EVs), from the patient peripheral blood fluids. These elements constitute a source of genomic and proteomic information for cancer treatment. Within the tumour-derived components of the body fluids, the enzyme indicated with the acronym CA IX and belonging to the superfamily of carbonic anhydrases (CA, EC 4.2.1.1) is a promising aspirant for checking tumours. CA IX is a transmembrane-CA isoform that is strongly overexpressed in many cancers being not much diffused in healthy tissues except the gastrointestinal tract. Here, it is summarised the role of CA IX as tumour-associated protein and its putative relationship in liquid biopsyfor diagnosing and monitoring cancer progression.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Liquid biopsy</kwd><kwd>cancer</kwd><kwd>carbonic anhydrase IX</kwd><kwd>tumour markers</kwd><kwd>acidification</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="6"/><word-count count="5430"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><sec id="s0002"><label>1.1.</label><title>Carbonic anhydrases (CAs)</title><p>A crucial physiological reaction for the survival of all living organisms is the pivotal CO<sub>2 </sub>hydration/dehydration of the central metabolism. This reaction is connected with numerous metabolic pathways, such as photosynthesis and carboxylation reactions, and biochemical pathways including pH homeostasis, secretion of electrolytes, transport of CO<sub>2</sub> and bicarbonate, and so on<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Moreover, the interconversion of CO<sub>2</sub> and HCO<sub>3</sub><sup>&#x02212;</sup> is spontaneously and precisely balanced form the living organisms to maintain the equilibrium between dissolved inorganic carbon dioxide (CO<sub>2</sub>), carbonic acid (H<sub>2</sub>CO<sub>3</sub>), bicarbonate (HCO<sub>3</sub><sup>&#x02212;</sup>) and carbonate (CO<sub>3</sub><sup>2&#x02212;</sup>)<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;6</sup></xref>. The CO<sub>2</sub> hydration/dehydration is catalysed by a superfamily of metalloenzymes, known as carbonic anhydrases (CAs, EC 4.2.1.1)<xref rid="CIT0007" ref-type="bibr"><sup>7&#x02013;11</sup></xref>, which are categorised into eight genetically distinct families (or classes), named with the Greek letters: &#x003b1;, &#x003b2;, &#x003b3;, &#x003b4;, &#x003b6;, &#x003b7;, &#x00275;, and &#x003b9;. The last three classes were recently discovered<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;14</sup></xref>. Moreover, members of each class possess multiple transcript variants and protein isoforms, which are characterised by different biochemical properties and have specific tissue/organ and sub-cellular localizations<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0015" ref-type="bibr"><sup>15&#x02013;20</sup></xref>. CAs present in animals belong to &#x003b1;-class<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>, plants and algae have &#x003b1;-, &#x003b2;-, &#x003b3;-, &#x003b4;- &#x003b8;- and &#x003b9;-classes; fungi encode for &#x003b1;- and &#x003b2;-CAs; protozoa for &#x003b1;-, &#x003b2;- and/or &#x003b7;-CAs; bacteria for &#x003b1;-, &#x003b2;-, &#x003b3;- and &#x003b9;-CA classes<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0023" ref-type="bibr"><sup>23&#x02013;27</sup></xref>. Besides, a matrix protein called nacrein has been identified in the oyster <italic>Pinctada fucata</italic>. It participates in the formation of the nacreous layer and is characterised by a CA domain present at the N-terminus part of the polypeptide sequence<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>. In mammals, 16 &#x003b1;-CA isoforms have been identified: five of them are cytosolic (CA I, CA II, CA III, CA VII, and CA XIII), five are membrane-bound (CA IV, CA IX, CA XII, CA XIV, and CA XV), two are mitochondrial (CA VA and CA VB), and only one is secreted (CA VI), the last three (CA VIII, CA X, and CA XI) being devoid of catalytic activity and referred to as CA Related Proteins (CARPs)<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>. CA active site includes a zinc ion (Zn<sup>2</sup><sup>+</sup>), which plays a critical role in the catalytic enzyme function. In addition to the zinc, &#x003b6;-and &#x003b3;-CAs reflect exceptions to this principle since they can use cadmium (&#x003b6;), iron (&#x003b3;), or cobalt (&#x003b3;)<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>.</p></sec><sec id="s0003"><label>1.2.</label><title>Tumour-associated CA IX</title><p>The glycolytic metabolism of cancer was evaluated for so many years to describe the fundamental role of tumour microenvironment and glycolysis in cancer growth and progression<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. The transcription factors of the glycolytic pathway affect cell proliferation, which is an essential feature of carcinogenesis<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. Different types of enzymes are produced by tumours or by the body in response to malignancy and used as cancer biomarkers<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>. It has been shown that the expression levels of certain enzymes can vary in various types of cancer<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>. CA IX is a transmembrane CA isoform expressed in healthy tissues. <xref ref-type="fig" rid="F0001">Figure 1</xref> shows the catalytically active CA IX on the cellular membrane surface<xref rid="CIT0036" ref-type="bibr"><sup>36&#x02013;38</sup></xref>. CA IX is highly overexpressed in many types of cancer<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref>. For example, its expression is increased considerably in solid tumours of uterus, kidney, lung, colon, breast, brain, and ovary<xref rid="CIT0041" ref-type="bibr"><sup>41&#x02013;44</sup></xref>. Tumour cells decrease their extracellular pH by lactic acid production and CO<sub>2</sub> hydration, which is catalysed by CAs (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Since the tumour-associated CA IX is an efficient catalyst for the conversion of CO<sub>2</sub> in bicarbonate and protons, they contribute to the acidification of the tumour environment. Moreover, its activity leads to the acquisition of metastatic phenotypes and chemoresistance to weakly basic anticancer drugs<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structure of CA IX isoenzyme. (PG: Proteoglycan domain; TM: Transmembrane domain; IC: Intracellular domain).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1697251_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>pH regulation of carbonic anhydrase enzymes in tumour cells.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1697251_F0002_C"/></fig><p>Interestingly, CA IX has a metastatic activity related to the extracellular acidity since it has been shown to promote migration and invasion in tumour cells<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref>. Furthermore, oxygen has a crucial function in the regulation of redox balance and energy production in tumour tissues. An inadequate amount of oxygen in the tissues causes hypoxia, which is a characteristic marker of the tumour microenvironment. Hypoxia regulates the expression of many genes inducing a phenotypic alteration of stromal cells in the tumour microenvironment and promoting the survival of cancer cells. Low oxygen activates the HIF-1, the hypoxia-inducible factor 1 (HIF-1)<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>, which starts the transcription of several hypoxia-inducible genes, such as (Vascular Endothelial Growth Factor (VEGF), Glucose Transporter 1 (GLUT1), CA IX and CA XII))<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. CA IX is one of the most potent hypoxia-induced proteins, and the hypoxia-inducible proteins are important anti-cancer targets<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>. As a result, it is readily apparent that CA IX is associated with many tumours and are involved in the cancer process<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. The specific inhibition of CA IX activity with selective inhibitors, such as sulphonamide derivatives, represents a good strategy for establishing the driving role of this isoform, as well as other CAs, for example, CA XII, in tumorigenesis<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref>. Many CA inhibitors exist, which could be classified as inhibitors binding the metal ion, inhibitors anchoring to the water molecule/hydroxide ion coordinated to the metal, inhibitors occluding the active site entrance and inhibitors linking out of the active site<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>. Many of these inhibitors can be used to reduce the proliferation and invasion capacity of cancer cells<xref rid="CIT0053" ref-type="bibr"><sup>53&#x02013;55</sup></xref>. Since pH-related cancer growth and metastasis might be dependent on the enzyme activity of the CA IX isoform, the identification of CA IX as tumour biomarker in the liquid biopsy is crucial for a new approach concerning the treatment of malignancy. The role of cancer markers in carcinogenesis is pivotal for early diagnosis, promotion of suitable procedures, and leading right management strategies<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>.</p></sec></sec><sec id="s0004"><label>2.</label><title>Tumour-derived components in liquid biopsy</title><p>Recently, liquid biopsy has begun an exciting approach in terms of early detection of tumor<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>. The technique, starting from the blood or body fluids, isolates tumour-derived components, such as circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and extracellular vesicles (EVs), as a source of genomic and proteomic information in patients with cancer<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. Liquid biopsy is an appropriate technique for correct treatments and figuring out the genetic changes in the tumour. It can be applied to many types of cancer, analysing the blood or body fluids of the patient taken in a non-invasive manner compared to the biopsy and without even detecting the symptoms<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>.</p><sec id="s0005"><label>2.1.</label><title>Circulating tumour cells (CTCs)</title><p>Thomas Ashworth investigated CTCs in the 1860s, considering that tumour cells could have crossed the vessel wall and enter the bloodstream<xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref>. These cells are released from primary or metastatic cells. A few steps are required for the metastatic process. First, CTCs are separated from the tumour and incorporated into the bloodstream. The circulating CTCs are then protected from the immune cells to perform extravasation. After that, these cells adapt to the microenvironment of the new tissue and to form metastatic lesions. CTCs are found in circulation as single CTCs or CTC clusters. In the literature, it has been reported that tumour progression and patient survival is correlated with the numbers of CTCs<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>. The cont of CTCs is also useful in the treatment response process. The technics known as immunophenotypic identification of cytokeratin, enzymatic methods, and RT-qPCR (reverse transcriptase quantitative polymerase chain reaction) are used to detect CTCs<xref rid="CIT0062" ref-type="bibr"><sup>62&#x02013;66</sup></xref>. The cell surface glycoprotein, EPCAM (Epithelial Cell Adhesion Molecule), which is highly expressed in epithelial cancer cells, serves as the primary antigen for CTCs detection. Moreover, with this method, prognostic information can be obtained in metastatic breast, colon, and prostate cancers. CTCsare subjected to genomic mapping<xref rid="CIT0062" ref-type="bibr"><sup>62&#x02013;66</sup></xref>, allowing a detailed analysis of the genes responsible for the uncontrolled growth of cells. Of course, the major drawbacks of this technique are (i) to distinguish cancer cells from millions of healthy cells; (ii) the detection of the kind of cancer.</p></sec><sec id="s0006"><label>2.2.</label><title>Circulating tumour DNA (ctDNA)</title><p>The presence of ctDNA in the blood is dated back in 1948s<xref rid="CIT0067" ref-type="bibr"><sup>67</sup></xref>. Although circulating cell-tumour DNA was first identified in 1948, it has only recently been investigated in &#x0201c;liquid biopsy&#x0201d; as cancer biomarkers<xref rid="CIT0068" ref-type="bibr"><sup>68</sup></xref>. Tumours release fragments of DNA into the circulatory system, which are detectable and specific to cancer. There are several advantages to assessing ctDNA. Sampling is non-invasive and inexpensive compared to the tissue biopsy. Besides, ctDNA testing can be easily and frequently repeated to monitor changes that occur during treatment, serving as an early indicator of recurrence, resistance, or metastasis<xref rid="CIT0069" ref-type="bibr"><sup>69</sup></xref>. Liquid biopsy is believed to exhibit tumour heterogeneity, as cells circulate from different regions of the tumour, and to obtain information in a shorter time<xref rid="CIT0069" ref-type="bibr"><sup>69</sup></xref>. CTCs and ctDNAs derived from primary or metastatic cells are abundant in blood. Both CTC and ctDNA provide prognostic information based on the number and level of events detected<xref rid="CIT0070" ref-type="bibr"><sup>70&#x02013;72</sup></xref> (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Comparison of CTCs and ctDNA.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Comparision</th><th align="center">CTCs</th><th align="center">ctDNA</th></tr></thead><tbody valign="top"><tr><td align="left">Origin</td><td align="left">&#x00130;ntact cells</td><td align="left">Released from apoptotic and necrotic cells</td></tr><tr><td align="left">Description</td><td align="left">Originates from primary tumours or metastasis</td><td align="left">DNA fragments in blood circulation</td></tr><tr><td align="left">Detection techniques</td><td align="left">Density/size based immunomagnetic and microfluidic techniques</td><td align="left">PCR or sequencing based</td></tr><tr><td align="left">Advantages</td><td align="left"><list list-type="bullet"><list-item><p>Allows for DNA, RNA, protein research</p></list-item><list-item><p>Research at single-cell level</p></list-item><list-item><p>Captured cells can be used for <italic>in&#x000a0;vitro</italic> or <italic>in&#x000a0;vivo</italic> studies</p></list-item><list-item><p>Clinically validated technology available (CellSearch System)</p></list-item></list></td><td align="left"><list list-type="bullet"><list-item><p>Easily isolated with kits</p></list-item><list-item><p>Can be stored for a long time</p></list-item><list-item><p>Gives more precise results</p></list-item><list-item><p>Clinically validated for EGFR mutations in non-small cell lung cancer</p></list-item></list></td></tr><tr><td align="left">Disadvantages</td><td align="left"><list list-type="bullet"><list-item><p>A small number of cells are obtained in non-metastatic conditions</p></list-item><list-item><p>Can not be stored for a long time</p></list-item><list-item><p>Detection steps are expensive</p></list-item></list></td><td align="left"><list list-type="bullet"><list-item><p>Prognostics and predictability are unclear</p></list-item><list-item><p>Only DNA sequence analysis can be performed</p></list-item><list-item><p>Known target mutations are needed</p></list-item></list></td></tr></tbody></table></table-wrap></sec><sec id="s0007"><label>2.3.</label><title>Extracellular vesicles (EVs)</title><p>Extracellular Vesicles (EVs) are lipid structures released from cells. EVs contain proteins and nucleic acids and play a role in cellular communication, immune regulation, and microenvironmental modulation<xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref>. Nanosized exosomes (70&#x02013;150&#x02009;nm) are the most prominent members of these so-called extracellular vesicles (EVs) and are released from body fluids such as urine, ascites, and plasma<xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref>. Moreover, they are liberated over all kinds of body cells (epithelium cells, haematopoietic cells, adipocytes, healthy and malignant cells)<xref rid="CIT0075" ref-type="bibr"><sup>75</sup></xref>, released in almost all cell types under physiological and pathophysiological conditions and mediate intercellular contacts<xref rid="CIT0076" ref-type="bibr"><sup>76</sup></xref>. A theranostic solution could be represented by the nanosized EVs, which may transmit biomarkers of diseases and/or vectors of therapeutic molecules, offering a unique opportunity to use a combination of different markers specifically expressed for tumour-derived EVs<xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="CIT0076" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="CIT0077" ref-type="bibr"><sup>77</sup></xref>. For example, Prostate-Specific Antigen (PSA) does not differentiate between benign prostatic hyperplasia (BPH) and a Prostate Cancer (PC), resulting in large numbers of unnecessary biopsies and missed diagnosis of cancer. Since exosomes are directly detectable in patient plasma, the plasmatic exosomes expressing PSA have the potential in distinguishing healthy individuals, BPH, and PC<sup>77</sup>. Recently, it has been demonstrated that neurodegenerative disorders, including Alzheimer&#x02019;s disease (AD), Parkinson, and amyotrophic lateral sclerosis, are correlated with extracellular vesicles. EVs have also been investigated in relation to infection caused by viruses, bacteria, fungi, protozoa, and helminths<xref rid="CIT0076" ref-type="bibr"><sup>76</sup></xref>. Such pathogens secrete EVs, and prions were even present in EVs.Finally, EVs seem to play key roles in autoimmune diseases<xref rid="CIT0076" ref-type="bibr"><sup>76</sup></xref>. EVs circulating in body fluids are valuable liquid biopsy biomarkers. Additionally, their protein concentration is higher in patients with advanced tumours<xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref>.</p></sec></sec><sec id="s0008"><label>3.</label><title>Tumour-associated CA IX as biomarker in liquid biopsy</title><p>The tumour-associated CA IX may be used as a cancer biomarker in the liquid biopsy technique. Carbonic anhydrase IX is a transmembrane enzyme<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref>, and it is involved in the growth and development of tumour cell adhesion<xref rid="CIT0079" ref-type="bibr"><sup>79</sup></xref><sup>,</sup><xref rid="CIT0080" ref-type="bibr"><sup>80</sup></xref>. There is an association between elevated serum levels of CA IX and CTCs<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>. This suggests a relationship between hypoxia and tumour cell circulation in the bloodstream. In the peripheral venous blood, it is also possible to find the soluble form of CA IX, which is released by proteolytic cleavage<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="CIT0081" ref-type="bibr"><sup>81</sup></xref>. For example, a high level of soluble CA IX was found in the serum of patients with renal cancer<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>. M&#x000fc;ller et&#x000a0;al. investigated the relationship between serum levels of CA IX and CTCs in metastatic breast cancer<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>. Their findings suggested that the CA IX activity level was higher in cancer types with a high number of CTCs. In this condition, it is expected a decrease in the patient&#x02019;s overall survival. Besides, CA IX disrupts cell-cell and cell-matrix interactions by triggering tumour acidification. As a consequence, CTCs separate from the primary tumour, and invasion occurs. Probably, CA IX inhibition could slow down the invasion process of CTCs.</p><p>During the tumour progression, exosomes and the metalloenzyme CA IX affect the growth and proliferation of the tumour. The relationship between exosomes and CA IX has been investigated using an <italic>in&#x000a0;vitro</italic> cellular model of human prostate carcinoma cell line cultured in different pH conditions. The results showed that the acidic microenvironment increased both the expression and activity of CA IX in cancer cells<xref rid="CIT0082" ref-type="bibr"><sup>82</sup></xref>. Besides, the number of exosomes released by the cancer cells was raised together with the upregulation of the CA IX<xref rid="CIT0082" ref-type="bibr"><sup>82</sup></xref>. These data strongly support that exosomes and CA IX are tumour-associated components and the enzyme CA IX is a cancer biomarker that could be used as valuable target of the liquid biopsy<xref rid="CIT0082" ref-type="bibr"><sup>82</sup></xref>. Horie et&#x000a0;al. demonstrated that CA IX exosomes were released from renal carcinoma cells<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. The quantity of exosomal CA IX is increased in hypoxia response, promoting upregulation of MMP-2, migration and tube formation, and may induce angiogenesis in the tumour microenvironment<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. Dorai and co-workers analysed the effect of increasing expression levels of CA IX in renal cancer cells. They showed that the level of released gangliocytes was positively correlated to that of exosomal CA IX expression<xref rid="CIT0083" ref-type="bibr"><sup>83</sup></xref>. Gangliosides play a critical role in cell adhesion, migration, and cell signalling<xref rid="CIT0084" ref-type="bibr"><sup>84</sup></xref>. Since CA IX induces the release of gangliocyte-containing exosomes, the exosomal CA IX may be a valuable biomarker of the carcinogenesis process.</p><p>CA IX expression is regulated exclusively by HIF-1&#x003b1;, rapidly increases in response to hypoxia, and is very important for maintaining the acidic pH of the tumor<xref rid="CIT0085" ref-type="bibr"><sup>85</sup></xref>. Brown-Glaberman proposed that the circulating CA IX could be considered as a biomarker for detecting the level of hypoxia and the upregulation of HIF-1&#x003b1;<xref rid="CIT0086" ref-type="bibr"><sup>86</sup></xref><sup>,</sup><xref rid="CIT0087" ref-type="bibr"><sup>87</sup></xref>. Circulating CA IX can be easily isolated from body fluids and considered a biomarker for different stages of cancers and the differentiation of local/advanced tumours. Malentacchi and coworkers to validate circulating CA IX as a tumour biomarker measuring the CA IX mRNA in the urine sediments of patients affected by kidney, prostate, and bladder cancers<xref rid="CIT0088" ref-type="bibr"><sup>88</sup></xref>. As a result, they associated the mRNACA IX expression in the tumour of urogenital origin. Liu et&#x000a0;al. have found that the combination of the CA IX/CD147 antibodies achieved higher efficiency in the NanoVelcro platform compared to EPCAM-based methods for capturing circulating cells coming from the renal carcinoma<xref rid="CIT0089" ref-type="bibr"><sup>89</sup></xref>.</p></sec><sec id="s0009"><label>4.</label><title>Conclusion</title><p>Liquid biopsy technology allows the detection of solid tumours, such as those involving lung, breast, and pancreatic, using the blood or other body fluids. Liquid biopsy can detect cancer-specific markers even in lesions that are too small to be recognised by other available methods, indicating that this method can be used early in cancer diagnosis. Among the known biomarkers of the liquid biopsy, the CA IXisoenzyme could be a promising candidate for tumour detection. In fact, the CA IX activity level is higher in cancer types with a high number of CTCs; the quantity of exosomal CA IX is increased in hypoxia response; the release of the exosomal gangliocyte is correlated to the exosomal CA IX expression increase; the circulating CA IX is associated to tumors of urogenital origin; CA IX disrupts cell-cell and cell-matrix interactions by triggering tumour acidification. In this context, the tumour-associated CA IX could be considered a valid biomarker of the non-invasive liquid biopsy, which is viewed as a technique that offers future research on precision diagnosis and treatment of tumours in a non-invasive manner. Moreover, CA IX could be a valid molecular target in the treatment of cancer.</p></sec></body><back><sec id="s0010"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Alric</surname><given-names>J</given-names></name></person-group>
<article-title>Interaction between starch breakdown, acetate assimilation, and photosynthetic cyclic electron flow in <italic>Chlamydomonas reinhardtii</italic></article-title>. <source>J Biol Chem</source>
<year>2012</year>;<volume>287</volume>:<fpage>26445</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">22692199</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tcherkez</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Boex-Fontvieille</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mahe</surname><given-names>A</given-names></name></person-group>
<article-title>Respiratory carbon fluxes in leaves</article-title><source>. Curr Opin Plant Biol</source>
<year>2012</year>;<volume>15</volume>:<fpage>308</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22244081</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Ferry</surname><given-names>JG</given-names></name></person-group>
<article-title>Prokaryotic carbonic anhydrases</article-title><source>. FEMS Microbiol Rev</source>
<year>2000</year>;<volume>24</volume>:<fpage>335</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">10978542</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Badger</surname><given-names>MR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bicarbonate binding activity of the CmpA protein of the cyanobacterium Synechococcus sp. strain PCC 7942 involved in active transport of bicarbonate</article-title>. <source>J Biol Chem</source>
<year>2000</year>;<volume>275</volume>:<fpage>20551</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">10779519</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ouahrani-Bettache</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Montero</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new beta-carbonic anhydrase from <italic>Brucella suis</italic>, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth</article-title>. <source>Bioorg Med Chem</source>
<year>2011</year>;<volume>19</volume>:<fpage>1172</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21251841</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Turtaut</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ouahrani-Bettache</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from <italic>Brucella suis</italic></article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>2277</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">20158185</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annunziato</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D&#x02019;Alba</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of new potential anti-infective compounds based on carbonic anhydrase inhibitors by rational target-focused repurposing approaches</article-title>. <source>ChemMedChem</source>
<year>2016</year>;<volume>11</volume>:<fpage>1904</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">27304878</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozensoy Guler</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>689</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">26118417</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Prete</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>De Luca</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfonamide inhibition studies of the beta-carbonic anhydrase from the pathogenic bacterium <italic>Vibrio cholerae</italic></article-title>. <source>Bioorg Med Chem</source>
<year>2016</year>;<volume>24</volume>:<fpage>1115</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26850377</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Prete</surname><given-names>S</given-names></name>, <name name-style="western"><surname>De Luca</surname><given-names>V</given-names></name>, <name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cloning, expression and purification of the complete domain of the eta-carbonic anhydrase from <italic>Plasmodium falciparum</italic></article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>54</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>An overview of the carbonic anhydrases from two pathogens of the oral cavity: <italic>Streptococcus mutans</italic> and <italic>Porphyromonas gingivalis</italic></article-title>. <source>Curr Top Med Chem</source>
<year>2016</year>;<volume>16</volume>:<fpage>2359</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">27072694</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Clement</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kosta</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new widespread subclass of carbonic anhydrase in marine phytoplankton</article-title>. <source>Isme J</source>
<year>2019</year>;<volume>13</volume>:<fpage>2094</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">31024153</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kikutani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nagasato</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Thylakoid luminal theta-carbonic anhydrase critical for growth and photosynthesis in the marine diatom <italic>Phaeodactylum tricornutum</italic></article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2016</year>;<volume>113</volume>:<fpage>9828</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27531955</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Prete</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>GM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum&#x02013;the eta-carbonic anhydrases</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2014</year>;<volume>24</volume>:<fpage>4389</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">25168745</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name></person-group>
<article-title>Biomedical applications of prokaryotic carbonic anhydrases</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>745</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">29973089</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase activators</article-title>. <source>Future Med Chem</source>
<year>2018</year>;<volume>10</volume>:<fpage>561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29478330</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name></person-group>
<article-title>An overview of the bacterial carbonic anhydrases</article-title>. <source>Metabolites</source>
<year>2017</year>;<volume>7</volume>:<fpage>56</fpage>&#x02013;<lpage>74</lpage>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name></person-group>
<article-title>Carbonic anhydrase from <italic>Porphyromonas gingivalis</italic> as a drug target</article-title>. <source>Pathogens</source>
<year>2017</year>;<volume>6</volume>:<fpage>30</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Advances in structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2017</year>;<volume>12</volume>:<fpage>61</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27783541</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Bacterial, fungal and protozoan carbonic anhydrases as drug targets</article-title>. <source>Expert Opin Ther Targets</source>
<year>2015</year>;<volume>19</volume>:<fpage>1689</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">26235676</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aspatwar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tolvanen</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Ortutay</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase related proteins: molecular biology and evolution</article-title>. <source>Subcell Biochem</source>
<year>2014</year>;<volume>75</volume>:<fpage>135</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">24146378</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases as drug targets&#x02013;an overview</article-title>. <source>Curr Top Med Chem</source>
<year>2007</year>;<volume>7</volume>:<fpage>825</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">17504127</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name></person-group>
<article-title>The eta-class carbonic anhydrases as drug targets for antimalarial agents</article-title>. <source>Expert Opin Ther Targets</source>
<year>2015</year>;<volume>19</volume>:<fpage>551</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25495426</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>An overview of the selectivity and efficiency of the bacterial carbonic anhydrase inhibitors</article-title>. <source>Curr Med Chem</source>
<year>2015</year>;<volume>22</volume>:<fpage>2130</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25312213</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2015</year>;<volume>30</volume>:<fpage>325</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">24766661</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Sulfa and trimethoprim-like drugs &#x02013; antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2014</year>;<volume>29</volume>:<fpage>379</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">23627736</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Anti-infective carbonic anhydrase inhibitors: a patent and literature review</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>693</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">23488877</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Miyashita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Okushima</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A carbonic anhydrase from the nacreous layer in oyster pearls</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1996</year>;<volume>93</volume>:<fpage>9657</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">8790386</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases&#x02013;an overview</article-title>. <source>Curr Pharm Des</source>
<year>2008</year>;<volume>14</volume>:<fpage>603</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">18336305</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of hypoxic tumors</article-title>. <source>Metabolites</source>
<year>2017</year>;<volume>7</volume>:<fpage>48</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Saito</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>George</surname><given-names>GN</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Biochemistry: a cadmium enzyme from a marine diatom</article-title>. <source>Nature</source>
<year>2005</year>;<volume>435</volume>:<fpage>42</fpage>.<pub-id pub-id-type="pmid">15875011</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferry</surname><given-names>JG</given-names></name></person-group>
<article-title>The gamma class of carbonic anhydrases</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1804</volume>:<fpage>374</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">19747990</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name></person-group>
<article-title>Cancer cell metabolism: implications for therapeutic targets</article-title>. <source>Exp Mol Med</source>
<year>2013</year>;<volume>45</volume>:<fpage>e45</fpage>.<pub-id pub-id-type="pmid">24091747</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Geronikaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Terzi</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase isoforms I, II, IX and XII with secondary sulfonamides incorporating benzothiazole scaffolds</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>1306</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26745009</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent advances in structural studies of the carbonic anhydrase family: the crystal structure of human CA IX and CA XIII</article-title>. <source>Curr Pharm Des</source>
<year>2010</year>;<volume>16</volume>:<fpage>3246</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">20819069</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilvo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baranauskiene</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Salzano</surname><given-names>AM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes</article-title>. <source>J Biol Chem</source>
<year>2008</year>;<volume>283</volume>:<fpage>27799</fpage>&#x02013;<lpage>809</lpage>.<pub-id pub-id-type="pmid">18703501</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Menchise</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2005</year>;<volume>15</volume>:<fpage>1937</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">15780637</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winum</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Rami</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX: a new druggable target for the design of antitumor agents</article-title>. <source>Med Res Rev</source>
<year>2008</year>;<volume>28</volume>:<fpage>445</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">17880011</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winum</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Pastorekova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jakubickova</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2005</year>;<volume>15</volume>:<fpage>579</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">15664816</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Berrino</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>83</volume>:<fpage>549</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30471577</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mboge</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wolff</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition</article-title>. <source>PLoS One</source>
<year>2018</year>;<volume>13</volume>:<fpage>e0207417</fpage>.<pub-id pub-id-type="pmid">30452451</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors</article-title>. <source>Expert Opin Investig Drugs</source>
<year>2018</year>;<volume>27</volume>:<fpage>963</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Al-Rashood</surname><given-names>ST</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in&#x000a0;vitro antitumor activity towards colon cancer</article-title>. <source>Bioorg Chem</source>
<year>2018</year>;<volume>81</volume>:<fpage>425</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">30219719</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Lerman</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Stanbridge</surname><given-names>EJ</given-names></name></person-group>
<article-title>Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development</article-title>. <source>BMC Dev Biol</source>
<year>2009</year>;<volume>9</volume>:<fpage>22</fpage>.<pub-id pub-id-type="pmid">19291313</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source>
<year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Riethdorf</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rack</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer</article-title>. <source>Breast Cancer Res</source>
<year>2011</year>;<volume>13</volume>:<fpage>R71</fpage>.<pub-id pub-id-type="pmid">21745383</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aspatwar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tolvanen</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Ortutay</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase related protein VIII and its role in neurodegeneration and cancer</article-title>. <source>Curr Pharm Des</source>
<year>2010</year>;<volume>16</volume>:<fpage>3264</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">20819067</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exosomes expressing carbonic anhydrase 9 promote angiogenesis</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2017</year>;<volume>492</volume>:<fpage>356</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">28851650</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zavada</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zavadova</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zat&#x02019;ovicova</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients</article-title>. <source>Br J Cancer</source>
<year>2003</year>;<volume>89</volume>:<fpage>1067</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">12966427</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Waheed</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sly</surname><given-names>WS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrases in the mouse harderian gland</article-title>. <source>J Mol Histol</source>
<year>2010</year>;<volume>41</volume>:<fpage>411</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20820888</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkkila</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rajaniemi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Parkkila</surname><given-names>AK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in&#x000a0;vitro</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2000</year>;<volume>97</volume>:<fpage>2220</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">10688890</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guler</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>C</given-names></name></person-group>
<article-title>Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII</article-title>. <source>Curr Med Chem</source>
<year>2010</year>;<volume>17</volume>:<fpage>1516</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">20166929</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monti</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name></person-group>
<article-title>Anticancer carbonic anhydrase inhibitors: a patent review (2008&#x02013;2013)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>737</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">23672415</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiumi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></name></person-group>
<article-title>[Possibility of metabolite biomarkers for early detection of cancer]</article-title>. <source>Gan to Kagaku Ryoho</source>
<year>2018</year>;<volume>45</volume>:<fpage>894</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30026409</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name></person-group>
<article-title>Circulating tumor DNA as biomarkers for cancer detection</article-title>. <source>Genomics Proteomics Bioinformatics</source>
<year>2017</year>;<volume>15</volume>:<fpage>59</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">28392479</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes?</article-title>
<source>Cell Physiol Biochem</source>
<year>2017</year>;<volume>41</volume>:<fpage>755</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28214887</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Offin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chabon</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Razavi</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Capturing genomic evolution of lung cancers through liquid biopsy for circulating tumor DNA</article-title>. <source>J Oncol</source>
<year>2017</year>;<volume>2017</volume>:<fpage>1</fpage>.</mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashworth</surname><given-names>TR</given-names></name></person-group>
<article-title>A case of cancer in which cells similar to those in the tumours were seen in the blood after death</article-title>. <source>Austr Med J</source>
<year>1869</year>;<volume>14</volume>:<fpage>146</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ogunwobi</surname><given-names>OO</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip</article-title>. <source>Lab Chip</source>
<year>2014</year>;<volume>14</volume>:<fpage>89</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">24220648</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>X</given-names></name></person-group>
<article-title>Advances of <italic>in&#x000a0;vivo</italic> flow cytometry on cancer studies</article-title>. <source>Cytometry A</source>
<year>2019</year>. [Epub ahead of print]. doi:<pub-id pub-id-type="doi">10.1002/cyto.a.23851</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khetani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mohammadi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nezhad</surname><given-names>AS</given-names></name></person-group>
<article-title>Filter-based isolation, enrichment, and characterization of circulating tumor cells</article-title>. <source>Biotechnol Bioeng</source>
<year>2018</year>;<volume>115</volume>:<fpage>2504</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">29989145</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werbin</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Nordberg</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Tzucker</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al</etal></person-group>
<article-title>RareCyte&#x000ae; CTC analysis step 2: detection of circulating tumor cells by CyteFinder&#x000ae; automated scanning and semiautomated image analysis</article-title>. <source>Methods Mol Biol</source>
<year>2017</year>;<volume>1634</volume>:<fpage>173</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">28819850</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Willmore</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>DeRosa</surname><given-names>MC</given-names></name></person-group>
<article-title>Aptamers: promising tools for the detection of circulating tumor cells</article-title>. <source>Nucleic Acid Ther</source>
<year>2016</year>;<volume>26</volume>:<fpage>335</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">27736306</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghossein</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group>
<article-title>Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas</article-title>. <source>Semin Surg Oncol</source>
<year>2001</year>;<volume>20</volume>:<fpage>304</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">11747272</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Metais</surname><given-names>P</given-names></name></person-group>
<article-title>Les acides nucl&#x000e9;iques du plasma sanguin chez l'homme</article-title>. <source>C R Seances Soc Biol Fil</source>
<year>1948</year>;<volume>142</volume>:<fpage>241</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">18875018</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bedard</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of genomic signatures in circulating tumor cells from breast cancer</article-title>. <source>Int J Cancer</source>
<year>2015</year>;<volume>137</volume>:<fpage>332</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">25529931</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Circulating tumor DNA detection: a potential tool for colorectal cancer management</article-title>. <source>Oncol Lett</source>
<year>2019</year>;<volume>17</volume>:<fpage>1409</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">30675194</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitzer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Auer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ulz</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Circulating tumor cells and DNA as liquid biopsies</article-title>. <source>Genome Med</source>
<year>2013</year>;<volume>5</volume>:<fpage>73</fpage>.<pub-id pub-id-type="pmid">23998943</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA)</article-title>. <source>Micromachines (Basel)</source>
<year>2018</year>;<volume>9</volume>. doi:<pub-id pub-id-type="doi">10.3390/mi9030100</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>MHD</given-names></name>, <name name-style="western"><surname>Bender</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Krahn</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>ctDNA and CTCs in liquid biopsy - current status and where we need to progress</article-title>. <source>Comput Struct Biotechnol J</source>
<year>2018</year>;<volume>16</volume>:<fpage>190</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">29977481</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Extracellular vesicles: a brief overview and its role in precision medicine</article-title>. <source>Methods Mol Biol</source>
<year>2017</year>;<volume>1660</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">28828643</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campanella</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Caruso Bavisotto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Logozzi</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>On the choice of the extracellular vesicles for therapeutic purposes</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>. doi:<pub-id pub-id-type="doi">10.3390/ijms20020236</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giannandrea</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lesma</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Extracellular vesicles enhance multiple myeloma metastatic dissemination</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>. doi: <pub-id pub-id-type="doi">10.3390/ijms20133236</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fais</surname><given-names>S</given-names></name>, <name name-style="western"><surname>O&#x02019;Driscoll</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Borras</surname><given-names>FE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine</article-title>. <source>ACS Nano</source>
<year>2016</year>;<volume>10</volume>:<fpage>3886</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">26978483</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logozzi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Angelini</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Giuliani</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Increased plasmatic levels of PSA-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: a prospective study</article-title>. <source>Cancers (Basel)</source>
<year>2019</year>;<volume>11</volume>. doi:<pub-id pub-id-type="doi">10.3390/cancers11101449</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1804</volume>:<fpage>404</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19679200</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svastova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Witarski</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Csaderova</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain</article-title>. <source>J Biol Chem</source>
<year>2012</year>;<volume>287</volume>:<fpage>3392</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">22170054</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one</article-title>. <source>Med Res Rev</source>
<year>2018</year>;<volume>38</volume>:<fpage>1799</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">29635752</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilie</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mazure</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Hofman</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer</article-title>. <source>Br J Cancer</source>
<year>2010</year>;<volume>102</volume>:<fpage>1627</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">20461082</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logozzi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Di Raimo</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>272</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30734594</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sawczuk</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Pastorek</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The role of carbonic anhydrase IX overexpression in kidney cancer</article-title>. <source>Eur J Cancer</source>
<year>2005</year>;<volume>41</volume>:<fpage>2935</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16310354</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murai</surname><given-names>T</given-names></name></person-group>
<article-title>The role of lipid rafts in cancer cell adhesion and migration</article-title>. <source>Int J Cell Biol</source>
<year>2012</year>;<volume>2012</volume>:<fpage>1</fpage>.</mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaluz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kaluzova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>SY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?</article-title>
<source>Biochim Biophys Acta</source>
<year>2009</year>;<volume>1795</volume>:<fpage>162</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">19344680</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown-Glaberman</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Marron</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chalasani</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Circulating carbonic anhydrase IX and antiangiogenic therapy in breast cancer</article-title>. <source>Dis Markers</source>
<year>2016</year>;<volume>2016</volume>:<fpage>1</fpage>.</mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finkelmeier</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Canli</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Peiffer</surname><given-names>KH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis</article-title>. <source>PLoS One</source>
<year>2018</year>;<volume>13</volume>:<fpage>e0200855</fpage>.<pub-id pub-id-type="pmid">30011326</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malentacchi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Vinci</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Melina</surname><given-names>AD</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers</article-title>. <source>Urol Oncol</source>
<year>2016</year>;<volume>34</volume>:<fpage>292</fpage> e9&#x02013;<lpage>292 e16</lpage>.</mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients</article-title>. <source>Oncotarget</source>
<year>2016</year>;<volume>7</volume>:<fpage>59877</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">27494883</pub-id></mixed-citation></ref></ref-list></back></article>